Sialyl Lewis A Monoclonal Antibody

Description

Sialyl Lewis A Monoclonal Antibody
Catalog number: B2011005
Lot number: Batch Dependent
Expiration Date: Batch dependent
Amount: 0.1 mg
Molecular Weight or Concentration: na
Supplied as: Solution
Applications: molecular tool for various immunological studies
Storage: -20C
Keywords: Anti-Sialyl Lewis A Monoclonal Antibody
Grade: Biotechnology grade. All products are highly pure. All solutions are made with Type I ultrapure water (resistivity >18 MΩ-cm) and are filtered through 0.22 um.

References:
1: Lee T, Teng TZJ, Shelat VG. Carbohydrate antigen 19-9 – tumor marker: Past, present, and future World J Gastrointest Surg. 2020 Dec 27;12(12):468-490.
2: Herfurth L, Ernst B, Wagner B, Ricklin D, Strasser DS, Magnani JL, Benie AJ, Peters T. Comparative epitope mapping with saturation transfer difference NMR of sialyl Lewis(a) compounds and derivatives bound to a monoclonal antibody J Med Chem. 2005 Nov 3;48(22):6879-86.
3: Gupta S, McDonald JD, Ayabe RI, Khan TM, Gamble LA, Sinha S, Hannah C, Blakely AM, Davis JL, Hernandez JM. Targeting CA 19-9 with a humanized monoclonal antibody at the time of surgery may decrease recurrence rates for patients undergoing resections for pancreatic cancer, cholangiocarcinoma and metastatic colorectal cancer J Gastrointest Oncol. 2020 Apr;11(2):231-235.
4: Sawada R, Sun SM, Wu X, Hong F, Ragupathi G, Livingston PO, Scholz WW. Human monoclonal antibodies to sialyl-Lewis (CA19.9) with potent CDC, ADCC, and antitumor activity Clin Cancer Res. 2011 Mar 1;17(5):1024-32.
5: Taga M, Hoshino H, Low S, Imamura Y, Ito H, Yokoyama O, Kobayashi M. A potential role for 6-sulfo sialyl Lewis X in metastasis of bladder urothelial carcinoma Urol Oncol. 2015 Nov;33(11):496.e1-9.
6: Baeckström D, Nilsson O, Price MR, Lindholm L, Hansson GC. Discrimination of MUC1 mucins from other sialyl-Le(a)-carrying glycoproteins produced by colon carcinoma cells using a novel monoclonal antibody Cancer Res. 1993 Feb 15;53(4):755-61.
7: Ragupathi G, Damani P, Srivastava G, Srivastava O, Sucheck SJ, Ichikawa Y, Livingston PO. Synthesis of sialyl Lewis(a) (sLe (a), CA19-9) and construction of an immunogenic sLe(a) vaccine Cancer Immunol Immunother. 2009 Sep;58(9):1397-405.
8: Nakayama T, Watanabe M, Katsumata T, Teramoto T, Kitajima M. Expression of sialyl Lewis(a) as a new prognostic factor for patients with advanced colorectal carcinoma Cancer. 1995 Apr 15;75(8):2051-6.
9: Jeschke U, Mylonas I, Shabani N, Kunert-Keil C, Schindlbeck C, Gerber B, Friese K. Expression of sialyl lewis X, sialyl Lewis A, E-cadherin and cathepsin-D in human breast cancer: immunohistochemical analysis in mammary carcinoma in situ, invasive carcinomas and their lymph node metastasis Anticancer Res. 2005 May-Jun;25(3A):1615-22.
10: Sikut R, Zhang K, Baeckström D, Hansson GC. Distinct sub-populations of carcinoma-associated MUC1 mucins as detected by the monoclonal antibody 9H8 and antibodies against the sialyl-Lewis a and sialyl-Lewis x epitopes in the circulation of breast-cancer patients Int J Cancer. 1996 May 29;66(5):617-23.

Products Related to Sialyl Lewis A Monoclonal Antibody: Antibodies